Hepatocellular carcinoma with sarcomatous change arising after eradication of HCV via interferon therapy

Clinical Imaging

Volumn 30, Issue 6, 2006, Pages 416-419

  Idobe Fujii, Youko ^a   Ogi, Nagako ^a   Hosho, Keiko ^b   Koda, Masahiko ^b   Murawaki, Yoshikazu ^b   Horie, Yasushi ^c  

^a Hitachi kinen hospital   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY HOSPITAL   (Japan)

Author keywords

HCV; Hepatocellular carcinoma; Interferon therapy; Sarcomatous change

Indexed keywords

DIAGNOSIS; DISEASES; DRUG THERAPY; TUMORS;

HCV; HEPATOCELLULAR CARCINOMA; INTERFERON THERAPY; SARCOMATOUS CHANGE;

MEDICAL PROBLEMS;

ALCOHOL; BETA INTERFERON;

AGED; ANGIOGRAPHY; ARTICLE; ARTIFICIAL EMBOLISM; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ERADICATION THERAPY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; VASCULAR TUMOR;

AGED; CARCINOMA, HEPATOCELLULAR; HEPATITIS C; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALE; TREATMENT OUTCOME; VASCULAR NEOPLASMS;

EID: 33750715434     PISSN: 08997071     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinimag.2006.07.004     Document Type: Article

References (21)

1. Lee S.S. Histological response to interferon alfa-based therapies in hepatitis C. Semin Liver Dis 24 (2004) 55-60
2. Tsuda N., Yuki N., Mochizuki K., Nagaoka T., Yamashiro M., Omura M., Hikiji K., and Kato M. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 74 (2004) 406-413
3. Yoshida H., Tateishi R., Arakawa Y., Sata M., Fujiyama S., Nishiguchi S., Ishibashi H., Yamada G., Yokosuka O., Shiratori Y., and Omata M. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 53 (2004) 425-430
4. Omata M., and Yoshida H. Prevention and treatment of hepatocellular carcinoma. Liver Transpl 10 (2004) S111-S114
5. Iwasaki Y., Takaguchi K., Ikeda H., Makino Y., Araki Y., Ando M., Kobashi H., Kobatake T., Tanaka R., Tomita M., Senoh T., Kawaguchi M., Shimoe T., Manabe K., Kita K., Shimamura J., Sagakuchi K., and Shiratori Y. Risk factors for hepatocellular carcinoma in hepatitis C patients with sustained virologic response to interferon therapy. Liver Int 24 (2004) 603-610
6. Makiyama A., Itoh Y., Kasahara A., Imai Y., Kawata S., Yoshioka K., Tusbouchi H., Kiyosawa K., Kakumu S., Okita K., Hayashi N., and Okanoue T. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 101 (2004) 1616-1622
7. Kasahara A., Hayashi N., Mochizuku K., Takayanagi M., Yoshioka K., Kakumu S., et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 27 (1998) 1394-1402
8. Ichida F., Tsuji T., Omata M., Ichida T., Inoue K., Kamimura T., Yamada G., Hino K., Yokosuka O., and Suzuki H. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 6 (1996) 112-119
9. Majima Y. Growth rate of hepatocellular carcinoma by ultrasonography and its clinical significance (in Japanese with English abstract). Acta Hepatol Jpn 25 (1984) 754-765
10. Larghi A., Tagger A., Crosignani A., Ribero M.L., Bruno S., Portera G., Battezzati P.M., Maggioni M., Fasola M., Zuin M., and Podda M. Clinical significance of HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy. J Med Virol 55 (1998) 7-11
11. Reichard O., Glaumann H., Fryden A., Norkrans G., Schvarcz R., Sönnerborg A., Yun Z.B., and Weiland O. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 21 (1995) 918-922
12. Balart L.A., Perrillo R., Roddenberry J., Regenstein F., Shim K.S., Shieh C., Taylor B., Dash S., and Gerber M.A. Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment. Gastroenterology 104 (1993) 1472-1477
13. Hu K.Q. Occult hepatitis B virus infection and its clinical implications. J Viral Hepatitis 9 (2002) 243-257
14. Torbenson M., and Thomas D.L. Occult hepatitis B. Lancet Infect Dis 2 (2002) 479-486
15. Fracanzani A.L., Taioli E., Sampietro M., Fatta E., Bertelli C., Fiorelli G., and Fargion S. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol 35 (2001) 498-503
16. Kojiro M., Sugihara S., Kakizoe S., Nakashima O., and Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol 23 (1989) 4-8
17. Komada N., Yamagata M., Komura K., Hayashi K., Maruyama T., Kataoka H., Koono M., and Tsubouchi H. Hepatocellular carcinoma with sarcomatous change arising in primary biliary cirrhosis. J Gastroenterol 32 (1997) 95-101
18. Morishita Y., Etori F., Sawada K., Kachi H., Yamada T., Kawamori T., and Tanaka T. Sarcomatous hepatocellular carcinoma with malignant ascites. A report of two cases. Acta Cytol 42 (1998) 759-764
19. Haratake J., and Horie A. An immunohistochemical study of sarcomatoid liver carcinomas. Cancer 68 (1991) 93-97
20. Yamaguchi R., Nakashima O., and Yano H. Hepatocellular carcinoma with sarcomatous change: a clinicopathological and immunohistochemical study of 6 surgical cases. Oncology Rep 4 (1997) 525-529
21. Koda M., Maeda Y., Matsunaga Y., Mimura K., Murawaki Y., and Horie Y. Hepatocellular carcinoma with sarcomatous change arising after radiofrequency ablation for well-differentiated hepatocellular carcinoma. Hepatol Res 27 (2003) 163-167